Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Terumo Set To Build On Long-Term VAD Investments With Upcoming Trials

This article was originally published in The Gray Sheet

Executive Summary

Terumo Corporation's long journey toward comercialization of the DuraHeart ventricular assist device is about to take a major step forward with the start of a U.S. "bridge-to-transplant" trial and the upcoming launch of a "destination therapy" trial
Advertisement

Related Content

Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
People In Brief
People In Brief
Thoratec Sends HeartWare Early Valentine: $282 Million Proposal Is Accepted
Thoratec Sends HeartWare Early Valentine: $282 Million Proposal Is Accepted

Topics

Advertisement
UsernamePublicRestriction

Register

MT027326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel